CymaBay Therapeutics
CymaBay Therapeutics, based in Newark, California, focuses on developing therapies for liver and other chronic diseases, notably evaluating seladelpar in primary biliary cholangitis (PBC).
Services
CymaBay Therapeutics focuses on developing therapies for liver and other chronic diseases with high unmet medical need. The company also offers expanded access to investigational drugs for patients with serious or life-threatening conditions. Additionally, CymaBay provides support through grants and giving, specifically targeting patient advocacy, research, and clinical education in primary biliary cholangitis (PBC).
Products
CymaBay Therapeutics is evaluating seladelpar in primary biliary cholangitis (PBC). Seladelpar has a unique mechanism of action that shows promise in treating chronic diseases. The drug has received Orphan Drug Designation from both the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA). It also holds Breakthrough Therapy Designation for early-stage PBC, including pruritus, from the FDA and PRIority MEdicine (PRIME) status from the EMA for PBC.
Clinical Trials
CymaBay Therapeutics is engaged in multiple clinical trials for primary biliary cholangitis (PBC). These include the IDEAL, AFFIRM, and RESPONSE trials. These trials are designed to evaluate the efficacy and safety of seladelpar in patients with PBC. The company's commitment to rigorous clinical testing reflects its dedication to advancing treatment options for liver diseases.
Collaborations
CymaBay Therapeutics collaborates with various organizations to improve the lives of patients with liver and other chronic diseases. These collaborations aim to enhance patient care through shared research, clinical trials, and educational initiatives. This cooperative approach is integral to the company's strategy for developing effective therapies and advancing medical knowledge in the field of chronic liver diseases.
Location
CymaBay Therapeutics is headquartered in Newark, California. This location serves as the central hub for its research, development, and operational activities. The company’s strategic location allows it to tap into the rich biotech and pharmaceutical ecosystem prevalent in the region.